 <h1>Dopar Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>levodopa</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about levodopa. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Dopar.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to levodopa: inhalation capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, levodopa (the active ingredient contained in Dopar) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking levodopa:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>difficulty in breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>chest pain or discomfort</li>
<li>confusion</li>
<li>cough producing mucus</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>muscle aches</li>
<li>sneezing</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>twitching, twisting, uncontrolled repetitive movements of the tongue, lips, face, arms, or legs</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of levodopa may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Discolored sputum or nasal discharge</li>
<li>falls</li>
<li>mouth or throat pain</li>
<li>nausea</li>
<li>pain in the arms or legs</li>
<li>skin scraping or tearing</li>
<li>trouble sleeping</li>
<li>vomiting</li>
</ul><p>
<!-- end inhalation capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to levodopa: compounding powder, inhalation capsule, oral capsule, oral tablet</i></p><h3>General</h3><p>The more commonly occurring adverse reactions have included cough, nausea, upper respiratory tract infection, and discolored sputum.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>In a crossover clinical study in subjects with mild or moderate asthma on a stable regimen of asthma medication (n=25), patients received orally inhaled drug 84 mg every 4 hours for a total of 3 doses and placebo.  Cough was reported by 60% of subjects following drug administration compared with 0% following placebo.  Ten subjects (40%) had temporary FEV1 reductions from baseline (between 15% and 59%), and 4 of these subjects also had a reduction in FEV1 following placebo.  Subjects with a reduction in FEV1 remained asymptomatic and did not require rescue treatment.</p><p><b>Very common</b> (10% or more): Cough (15%)</p>
<p><b>Common</b> (1% to 10%): Discolored sputum, nasal discharge discoloration, oropharyngeal pain, upper respiratory tract infection, nasopharyngitis, bronchitis/pneumonia</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dyskinesia, headache</p>
<p><b>Frequency not reported</b>: Falling asleep during activities of daily living, somnolence</p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting</p><h3>Psychiatric</h3><p>During clinical trials, hallucinations were reported in less than 2% of patients receiving orally inhaled levodopa (the active ingredient contained in Dopar) </p><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Frequency not reported</b>: Hallucinations</p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest discomfort, orthostatic hypotension/blood pressure decreased</p><h3>Dermatologic</h3><p>Dermatologic</p>
<p><b>Common</b> (1% to 10%): Laceration, skin abrasion</p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased blood bilirubin</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Extremity pain</p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Decreased red blood cell count</p><h3>Other</h3><p>Fever, altered consciousness, autonomic dysfunction and muscle rigidity are the hallmarks of the neuroleptic malignant syndrome.  The neuroleptic malignant syndrome (NMS) is associated with a case fatality rate of about 20%.  If withdrawal of dopaminergic therapy is suspected as the cause of NMS, dopaminergic therapy should be restarted.  If a neuroleptic agent is suspected as the cause, the neuroleptic agent should be immediately discontinued.  For patients with NMS suspected to be due to neuroleptic therapy, consideration should be given to dantrolene (or bromocriptine) administration.  Intensive monitoring and supportive care are indicated for all patients with NMS.</p><p><b>Common</b> (1% to 10%): Fall</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Inbrija (levodopa)." Acorda Therapeutics, Hawthorne, NY. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between carbidopa, levodopa, and Rytary?</li>
<li>How does it help Parkinson's disease?</li>
<li>How much does Inbrija cost?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Dopar (levodopa)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Inbrija</dd></dl>
<h3>Professional resources</h3>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Parkinson's Disease</li>
<li>Periodic Limb Movement Disorder</li>
<li>Restless Legs Syndrome</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to levodopa: compounding powder, inhalation capsule, oral capsule, oral tablet</i></p><h3>General</h3><p>The more commonly occurring adverse reactions have included cough, nausea, upper respiratory tract infection, and discolored sputum.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>In a crossover clinical study in subjects with mild or moderate asthma on a stable regimen of asthma medication (n=25), patients received orally inhaled drug 84 mg every 4 hours for a total of 3 doses and placebo.  Cough was reported by 60% of subjects following drug administration compared with 0% following placebo.  Ten subjects (40%) had temporary FEV1 reductions from baseline (between 15% and 59%), and 4 of these subjects also had a reduction in FEV1 following placebo.  Subjects with a reduction in FEV1 remained asymptomatic and did not require rescue treatment.</p><p><b>Very common</b> (10% or more): Cough (15%)</p><p><b>Common</b> (1% to 10%): Discolored sputum, nasal discharge discoloration, oropharyngeal pain, upper respiratory tract infection, nasopharyngitis, bronchitis/pneumonia</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dyskinesia, headache</p><p><b>Frequency not reported</b>: Falling asleep during activities of daily living, somnolence</p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting</p><h3>Psychiatric</h3><p>During clinical trials, hallucinations were reported in less than 2% of patients receiving orally inhaled levodopa (the active ingredient contained in Dopar) </p><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Frequency not reported</b>: Hallucinations</p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest discomfort, orthostatic hypotension/blood pressure decreased</p><h3>Dermatologic</h3><p>Dermatologic</p><p><b>Common</b> (1% to 10%): Laceration, skin abrasion</p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased blood bilirubin</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Extremity pain</p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Decreased red blood cell count</p><h3>Other</h3><p>Fever, altered consciousness, autonomic dysfunction and muscle rigidity are the hallmarks of the neuroleptic malignant syndrome.  The neuroleptic malignant syndrome (NMS) is associated with a case fatality rate of about 20%.  If withdrawal of dopaminergic therapy is suspected as the cause of NMS, dopaminergic therapy should be restarted.  If a neuroleptic agent is suspected as the cause, the neuroleptic agent should be immediately discontinued.  For patients with NMS suspected to be due to neuroleptic therapy, consideration should be given to dantrolene (or bromocriptine) administration.  Intensive monitoring and supportive care are indicated for all patients with NMS.</p><p><b>Common</b> (1% to 10%): Fall</p><p id="ref_1">1. "Product Information. Inbrija (levodopa)." Acorda Therapeutics, Hawthorne, NY. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between carbidopa, levodopa, and Rytary?</li>
<li>How does it help Parkinson's disease?</li>
<li>How much does Inbrija cost?</li>
</ul><h2>More about Dopar (levodopa)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Parkinson's Disease</li>
<li>Periodic Limb Movement Disorder</li>
<li>Restless Legs Syndrome</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>